Andrographis 用于 Upper Respiratory Tract Infections

Q: Does Andrographis help with Upper Respiratory Tract Infections?

Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).

Q: How much Andrographis should I take for Upper Respiratory Tract Infections?

Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.

Q: Are there side effects of Andrographis?

Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

Q: How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?

We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

Multiple randomized controlled trials and Cochrane-reviewed meta-analyses support andrographis for reducing the severity and duration of upper respiratory symptoms. One of the most evidence-backed herbal supplements for acute respiratory infections.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dandrographis\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

结论

Key Study Findings

Randomized Controlled Trial n=331 1.0 weeks Double-blind

Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common …

Dose: 200 mg/day vs: placebo Outcome: URTI symptom severity 效果: None p = 0.034

研究人群: Participants with uncomplicated URTI

Review

A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead …

Dose: None vs: None Outcome: URTI symptom severity 效果: None None

研究人群: COVID-19/URTI patients

Review

Plant-Based Support of Respiratory Health during Viral Outbreaks.

Dose: None vs: None Outcome: None 效果: None None

研究人群: None

Other n=179

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study.

Dose: 60 mg vs: placebo Outcome: None 效果: None p = 0.0053

研究人群: None

Meta-Analysis n=1000

Safety of Andrographis paniculata: A systematic review and meta-analysis.

Dose: 95% vs: control Outcome: None 效果: None None

研究人群: upper respiratory tract infection

Other

In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa.

Dose: 6 μg/mL vs: Control group Outcome: None 效果: None None

研究人群: None

Key Statistics

研究数量

800

受试者

↑

Positive

等级

Referenced Papers

Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, … RCT

Complementary therapies in … 2023 6 次引用

A Comprehensive Review of Andrographis paniculata (Burm. f.) Nees and Its Constituents as Potential Lead Compounds for COVID-19 Drug Discovery. Review

Molecules (Basel, Switzerland) 2022 80 次引用

Plant-Based Support of Respiratory Health during Viral Outbreaks. Other

Journal of agricultural … 2022 9 次引用

Safety of Andrographis paniculata: A systematic review and meta-analysis. Meta-Analysis

Pharmacoepidemiology and drug … 2021 32 次引用

Early intervention with Kan Jang® to treat upper-respiratory tract infections: A randomized, quadruple-blind study. Other

Journal of traditional … 2021 9 次引用

In vitro anti-biofilm activity of 14-deoxy-11,12-didehydroandrographolide from Andrographis paniculata against Pseudomonas aeruginosa. Other

Brazilian journal of … 2020 45 次引用

Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. Other

Cell death & … 2019 160 次引用

A review for the neuroprotective effects of andrographolide in the central nervous system. Review

Biomedicine & pharmacotherapy … 2019 103 次引用

A randomized double blind placebo controlled clinical evaluation of extract of Andrographis paniculata (KalmCold) in patients with uncomplicated upper respiratory … RCT

Phytomedicine : international … 2010 107 次引用

Colds and influenza: a review of diagnosis and conventional, botanical, and nutritional considerations. Review

Alternative medicine review … 2007 163 次引用

Complementary and alternative medicine for upper-respiratory-tract infection in children. Review

American journal of … 2006 51 次引用

Andrographis paniculata in the treatment of upper respiratory tract infections: a systematic review of safety and efficacy. Systematic Review

Planta medica 2004 262 次引用

Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials. Systematic Review

Journal of clinical … 2004 157 次引用

Respiratory and allergic diseases: from upper respiratory tract infections to asthma. Review

Primary care 2002 56 次引用

Undetectable anti-bacterial activity of Andrographis paniculata (Burma) wall. ex ness. RCT

Journal of the … 1990

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

常用剂量

acute:: 400 mg 3x/day for up to 7 days
general:: 200 mg standardized extract (30% andrographolides) 2x/day

上限： No established UL; short-term use (<14 days)

研究中使用的剂量

剂量	持续时间	效果	N
200 mg/day	1.0 weeks	Positive	331
None	--	Positive	--
None	--	Mixed	--
60 mg	--	Positive	179
95%	--	Neutral	1000
6 μg/mL	--	Positive	--
None	--	Mixed	--
18 G	4.0 weeks	Mixed	--

最佳服用时间： At first sign of symptoms; with meals

Safety & Side Effects

已报告的副作用

⚠ Gastrointestinal discomfort (nausea, diarrhea)
⚠ Headache
⚠ Fatigue
⚠ Allergic reactions (rare)
⚠ Potential anti-fertility effects (high doses in animal studies)

已知相互作用

● Anticoagulant and antiplatelet drugs (may increase bleeding risk)
● Antihypertensive medications (additive blood pressure lowering)
● Immunosuppressant medications (may counteract immunosuppression)

可耐受最高摄入量： No established UL; short-term use (<14 days)

在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。

Frequently Asked Questions

Does Andrographis help with Upper Respiratory Tract Infections?

Based on 7 studies with 800 participants, there is moderate evidence from clinical studies that Andrographis may support Upper Respiratory Tract Infections management. Our evidence grade is B (Good Evidence).

How much Andrographis should I take for Upper Respiratory Tract Infections?

Studies have used various dosages. A commonly studied range is 400 mg 3x/day for up to 7 days. Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Andrographis?

Reported side effects may include Gastrointestinal discomfort (nausea, diarrhea), Headache, Fatigue, Allergic reactions (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Andrographis and Upper Respiratory Tract Infections?

We rate the evidence as Grade B (Good Evidence). This rating is based on 7 peer-reviewed studies with 800 total participants. The overall direction of effect is positive.

Related Evidence

其他成分用于 Upper Respiratory Tract Infections

Vitamin D A Zinc A Beta-Glucan A Vitamin C B Echinacea B Garlic B

快速结论

Evidence Strength72%

High confidence

研究分析

RCT (3)Meta (1)Other (3)

对比替代方案

查看其他成分针对该健康状况的对比结果。

查看所有成分用于 Upper Respiratory Tract Infections

了解更多

FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。